Novel octreotide dicarba-analogues with high affinity and different selectivity for somatostatin receptors

Journal of Medicinal Chemistry

Volumn 53, Issue 16, 2010, Pages 6188-6197

  Di Cianni, Alessandra ^a   Carotenuto, Alfonso ^b   Brancaccio, Diego ^b   Novellino, Ettore ^b   Reubi, Jean Claude ^c   Beetschen, Karin ^c   Papini, Anna Maria ^a   Ginanneschi, Mauro ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

OCTREOTIDE; OCTREOTIDE DICARBA DERIVATIVE; SOMATOSTATIN 28; SOMATOSTATIN RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BINDING; DRUG PURIFICATION; DRUG SYNTHESIS; HUMAN; HUMAN CELL; NUCLEAR MAGNETIC RESONANCE; STRUCTURE ACTIVITY RELATION;

ANIMALS; CELL LINE; CRICETINAE; CRICETULUS; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MICELLES; MODELS, MOLECULAR; MOLECULAR CONFORMATION; OCTREOTIDE; RADIOLIGAND ASSAY; RECEPTORS, SOMATOSTATIN; SODIUM DODECYL SULFATE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77955908499     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm1005868     Document Type: Article

References (49)

1. Burgus, R.; Brazeau, P.; Vale, W. W. Isolation and determination of the primary structure of somatostatin (a somatotropin release inhibiting factor) of bovin hypothalamic origin. Advances in Human Growth Hormone Research, Report no. 74-612; U.S. Government Printing Office, DHEW, (NIH): Washington, DC, 1973; pp 144 - 158.
2. Weckbecker, G.; Lewis, I.; Albert, R.; Schmid, H. A.; Hoyer, D.; Bruns, C. Opportunities in somatostatin research: biological, chemical and therapeutical aspects Nature Rev. Drug Discovery 2003, 2, 999-1018
3. 1) selective analogues J. Med. Chem. 2009, 52, 2733-2764 and references therein.
4. Grace, C. R. R.; Erchegyi, J.; Koerber, S. C.; Reubi, J. C.; Rivier, J. E.; Riek, R. Novel sst2-selective somatostatin agonists. Three-dimensional consensus structure by NMR J. Med. Chem. 2006, 49, 4487-4496
5. Gairì, M.; Saiz, P.; Madurga, S.; Roig, X.; Erchegyi, J.; Koerber, S. C.; Reubi, J. C.; Rivier, J. E.; Giralt, E. Conformational analysis of a potent SSTR3-selective somatostatin analogue by NMR in water solution J. Pept. Sci. 2006, 12, 82-91
6. Grace, C. R.; Koerber, S. C.; Erchegyi, J.; Reubi, J. C.; Rivier, J.; Riek, R. Novel sst(4)-selective somatostatin (SRIF) agonists. 4. Three-dimensional consensus structure by NMR J. Med. Chem. 2003, 46, 5606-5618
7. Bauer, W.; Briner, U.; Dopfener, W.; Haller, R.; Huguenin, R.; Marbach, P.; Petcher, T. J.; Pless, J. SMS 201-995: a very potent and selective analogue of somatostatin with prolonged action Life Sci. 1982, 31, 1133-1140
8. Ginj, M.; Schmitt, J. S.; Chen, J.; Waser, B.; Reubi, J. C.; de Jong, M.; Schulz, S.; Mäcke, H. R. Design, synthesis, and biological evaluation of somatostatin-based radiopeptides Chem. Biol. 2006, 13, 1081-1090
9. Ginj, M.; Zhang, H.; Waser, B.; Cescato, R.; Wild, D.; Wang, X.; Erchegyi, J.; Rivier, J.; Mäcke, H.; R. Reubi, J. C. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 16436-16441
10. de Jong, M.; Breeman, W. A. P.; Kwekkenboom, D. J.; Valkema, R; Krenning, E. P. Tumor imaging and therapy using radiolabeled somatostatin analogues Acc. Chem. Res. 2009, 42, 873-880 and references therein.
11. Fichna, J.; Janecka, A. Synthesis of target-specific radiolabeled peptides for diagnostic imaging Bioconjugate Chem. 2003, 14, 3-17
12. Carotenuto, A.; D'Addona, D.; Rivalta, E.; Chelli, M.; Papini, A. M.; Rovero, P.; Ginanneschi, M. Synthesis of a dicarba-analogue of octreotide keeping the type II′ β-turn of the farmacophore in water solution Lett. Org. Chem. 2005, 2, 274-279
13. D'Addona, D.; Carotenuto, A.; Novellino, E.; Piccand, V.; Reubi, J. C.; Di Cianni, A; Gori, F.; Papini, A. M.; Ginanneschi, M. Novel sst5-selective somatostatin dicarba anlogues: synthesis and conformation-affinity relationships J. Med. Chem. 2008, 51, 512-520
14. Barragán, F.; Moreno, V.; Marchan, V. Solid-phase synthesis and DNA binding studies of dichloroplatinum(II) conjugates of dicarba analogues of octreotide as new anticancer drugs Chem. Commun. 2009, 4705-4707
15. Wütrich, K. NMR of Proteins and Nucleic Acids; John Wiley & Sons, Inc: New York, 1986.
16. Braunschweiler, L.; Ernst, R. R. Coherence Transfer by isotropic mixing: application to proton correlation spectroscopy J. Magn. Reson. 1983, 53, 521-528
17. Jenner, J.; Meyer, B. H.; Bachman, P.; Ernst, R. R. Investigation of exchange processes by two-dimensional NMR spectroscopy J. Chem. Phys. 1979, 71, 4546-4553
18. Bartels, C.; Xia, T.; Billeter, M.; Güntert, P.; Wüthrich, K. The program XEASY for computer-supported NMR spectral analysis of biological macromolecules J. Biomol. NMR 1995, 6, 1-10
19. Güntert, P.; Mumenthaler, C.; Wütrich, K. Torsion angle dynamics for NMR structure calculation with the new program DYANA J. Mol. Biol. 1997, 273, 283-298
20. Arison, B. H.; Hirschmann, R.; Veber, D. F. Inferences about the conformation of somatostatin at a biologic receptor based on NMR studies Bioorg. Chem. 1978, 7, 447-451
21. Wild, D.; Schmitt, J. S.; Ginj, M.; Mäcke, H. R.; Bernard, B. F.; Krenning, E.; de Jong, M.; Wenger, S.; Reubi, J. C. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals Eur. J. Med. Mol. Imaging 2003, 30, 1338-1347
22. Moroder, L.; Romano, R.; Guba, W.; Mierke, D. F.; Kessler, H.; Delporte, C.; Winand, J.; Christophe, J. New evidence for a membrane bound pathway in hormone receptor binding Biochemistry 1993, 32, 13551-13559
23. Wienk, H. L.; Wechselberger, R. W.; Czisch, M.; de Kruijff, B. Structure, dynamics, and insertion of a chloroplast targeting peptide in mixed micelles Biochemistry 2000, 39, 8219-8227
24. Bryson, E. A.; Rankin, S. E.; Carey, M.; Watts, A.; Pinheiro, T. J. Folding of apocytochrome c in lipid micelles: formation of α helix precedes membrane insertion Biochemistry 1999, 38, 9758-9767
25. Yamamoto, T.; Nair, P.; Jacobsen, N. E.; Davis, P.; Ma, S. W.; Navratilova, E.; Moye, S.; Lai, J.; Yamamura, H. I.; Vanderah, T. W.; Porreca, F.; Hruby, V. J. The importance of micelle-bound states for the bioactivities of bifunctional peptide derivatives for δ/μ opioid receptor agonists and neurokinin 1 receptor antagonists J. Med. Chem. 2008, 51, 6334-6347
26. Sargent, D. F.; Schwyzer, R. Membrane lipid phase as catalyst for peptide-receptor interactions Proc. Natl. Acad. Sci. U.S.A. 1986, 83, 5774-5778
27. Grieco, P.; Carotenuto, A.; Campiglia, P.; Gomez-Monterrey, I.; Auriemma, L.; Sala, M.; Marcozzi, C.; d'Emmanuele di Villa Bianca, R.; Brancaccio, D.; Rovero, P.; Santicioli, P.; Meini, S.; Maggi, C. A.; Novellino, E. New insight into the binding mode of peptide ligands at Urotensin-II receptor: structure-activity relationships study on P5U and Urantide J. Med. Chem. 2009, 52, 3927-3940
28. Melacini, G.; Zhu, Q.; Goodman, M. Multiconformational NMR analysis of sandostatin (octreotide): equilibrium between beta-sheet and partially helical structures Biochemistry 1997, 36, 1233-1241
29. Tyndall, J. D. A.; Pfeiffer, B.; Abbenante, G.; Fairlie, D. P. Over one hundred peptide-activated G protein-coupled receptors recognize ligands with turn structure Chem. Rev. 2005, 105, 793-826
30. Melacini, G.; Zhu, Q.; Osapay, G.; Goodman, M. A. Refined model for the somatostatin pharmacophore: conformational analysis of lanthionine-sandostatin analogs J. Med. Chem. 1997, 40, 2252-2258
31. Brady, S. F.; Paleveda, W. J.; Arison, B. H.; Saperstein, R.; Brady, E. J.; Raynor, K.; Reisine, T.; Veber, D. F.; Freidinger, R. M. Approaches to peptidomimetics which serve as surrogates for the cis amide bond: novel disulfide-constrained bicyclic hexapeptide analogs of somatostatin Tetrahedron 1993, 49, 3449-3466
32. Lewis, I.; Bauer, W.; Albert, R.; Chandramouli, N.; Pless, J.; Weckbecker, G.; Bruns, C. A novel somatostatin mimic with broad somatotropine release inhibitory factor receptor binding and superior therapeutic potential J. Med. Chem. 2003, 46, 2334-2344
33. Pohl, E.; Heine, A.; Sheldrick, G. M.; Dauter, Z.; Wilson, K. S.; Kallen, J.; Huber, W.; Pfaffli, P. J. Structure of octreotide, a somatostatin analog Acta Crystallogr., Sect. D: Biol. Crystallogr. 1995, 51, 48-59
34. Interlandi, G. Backbone conformations and side chain flexibility of two somatostatin mimics investigated by molecular dynamics simulations Proteins 2009, 75, 659-670
35. Reubi, J. C.; Waser, B.; Schaer, J.; Laissue, J. A. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands Eur. J. Nucl. Med. 2001, 28, 836-846
36. Zatelli, M. C.; degli Umberti, E. The significance of new somatostatin analogs as therapeutic agents Curr. Opin. Invest. Drugs 2009, 10, 1025-1031
37. Ben-Shlomo, A.; Melmed, S. Pasireotide-A somatostatin analog for the potential treatment of acromegaly, neuroendocrine tumors and Cushing's disease IDrugs 2007, 10, 885-895
38. Cescato, R.; Loesch, K. A.; Waser, B.; Mäcke, H. R.; Rivier, J. E.; Reubi, J. C.; Schonbrunn, A. Agonist-biased signaling at the sst2A receptor: the multi-somatostatin analogs KE108 and SOM230 activate and antagonize distinct signaling pathways Mol. Endocrinol. 2010, 24, 240-249
39. Antunes, P.; Ginj, M.; Walter, M. A.; Chen, J.; Reubi, J. C.; Mäcke, H. R. Influence of different spacers on the biological profile of a DOTA-somatostatin analogue Bioconjugate Chem. 2007, 18, 84-92
40. Nothacker, H. P.; Wang, Z.; McNeill, A. M.; Saito, Y.; Merten, S.; O'Dowd, B.; Duckles, S. P.; Civelli, O. Identification of the natural ligand of an orphan G-protein-coupled receptor involved in the regulation of vasoconstriction Nature Cell Biol. 1999, 1, 383-385
41. Malagon, M. M.; Molina, M.; Gahete, M. D.; Duran-Prado, M.; Martinez-Fuentes, A. J.; Alcain, F. J.; Tonon, M. C.; Leprince, J.; Vaudry, H.; Castaño, J. P.; Vazquez-Martinez, R. Urotensin II and urotensin II-related peptide activate somatostatin receptor subtypes 2 and 5 Peptides 2008, 29, 711-720
42. Stewart, J. M.; Young, J. D. In Solid Phase Peptide Synthesis, 2nd ed.; Pierce Chemical Company: Rockford, IL, 1984.
43. Hwang, T. L.; Shaka, A. J. Water suppression that works. Excitation sculpting using arbitrary wave-forms and pulsed-field gradients J. Magn. Reson. 1995, 112, 275-279
44. States, D. J.; Haberkorn, R. A.; Ruben, D. J. A two-dimensional nuclear Overhauser experiment with pure absorption phase four quadrants J. Magn. Reson. 1982, 48, 286-292
45. Maple, J.; Dinur, U.; Hagler, A. T. Derivation of force field for molecular mechanics and dynamics from ab initio energy surface Proc. Natl. Acad. Sci. U.S.A. 1988, 85, 5350-5354
46. Pettersen, E. F.; Goddard, T. D.; Huang, C. C.; Couch, G. S.; Greenblatt, D. M.; Meng, E. C.; Ferrin, T. E. UCSF Chimera-a visualization system for exploratory research and analysis J. Comput. Chem. 2004, 25, 1605-1612
47. Koradi, R.; Billeter, M.; Wüthrich, K. MOLMOL: a program for display and analysis of macromolecular structures J. Mol. Graphics 1996, 14, 51-55
48. 5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use Eur. J. Nucl. Med. 2000, 27, 273-282
49. 2-selective somatostatin antagonists suitable for radiotargeting J. Med. Chem. 2008, 51, 4030-4037